Monoclonal Antibodies

In vitro immunization of mouse spleen cells using protein and peptide antigens; immunodiagnosis of pancreatic cancers; idiotypic approach to the production of monoclonal antibodies against a human tumour-associated antigen; biochemical and biological characterization of the mouse/human chimaeric MBr1; reshaping of human antibodies using CDR-grafting; human antibodies and host recognition of ovarian carcinoma antigens; antireceptor antibody structure and peptide design; expression of antibody-ricin A chain fusions in mammalian cells; dosimetry of radiolabelled antibodies; radioimmunoimaging of squamous cell carcinoma; enhancement of tumour dose via antibody radiohalogenation; improved MB-1 delivery to lymphoma by predosing; intraperitoneal dosimetry of radiolabelled antibodies; biodistribution of polylysire guided radionuclides; monoclonal antibody uptake and distribution following intratumour injection; Indium-111 and Yttrium-90 labelled macrocyclic chelating agents; generation of bispecific monoclonal antibodies for two-phase radio-immunotherapy; cytotoxicity following specific activation of amygdalon; endogenous activation of a proding in antibody-directed enzyme proding therapy; application of matrix-conjugated monoclonal antibodies in enzyme isolation and analysis; evaluation of CA-549 in breast cancer; monoclonal antibodies; 323/A3 expression in potassium cysts of the breast; tamoxifen and oestradiol-regulated 24K protein expression; the role of radiolabelled antibodies in cancer diagnosis; hand-guided probes in intrasurgical radioimmunodetection; localization and immunohistochemistry of human gliomas using MUC 2-63; antibody uptake non-small cell lung cancer following irradiation; monoclonal antibody uptake by bladder carcinomas following intravesical administration; intraperitoneal radioimmunotherapy with stable Yttrium-90-labelled immunoconjugates; T cell proliferation following monoclonal antibody treatment; anti-idiotypes in cancer immunotherapy; chimeric monoclonal antibody studies in colorectal cancer; early clinical results with 99cm Tc-labelled F(ab)2; lymphoscintigraphy with recombinant epidermal-growth-factor in uterine cervical cancer.